These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

65 related articles for article (PubMed ID: 4447750)

  • 1. [Medroxyprogesterone (map) in massive doses in oncology: effects of treatment on the ECG in a group of patients with advanced breast carcinoma].
    Pannuti F; Pollutri E; Martoni A; Camera P; Lenaz GR
    Boll Soc Ital Biol Sper; 1974 May; 50(9):557-61. PubMed ID: 4447750
    [No Abstract]   [Full Text] [Related]  

  • 2. [Oral high doses of medroxyprogesterone acetate (MPA) in the treatment of advanced phases of breast and endometrial cancer].
    Bernardo-Strada MR; Imparato E; Aspesi G; Pavesi L; Robustelli Della Cuna G
    Minerva Med; 1980 Nov; 71(44):3241-6. PubMed ID: 7454090
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral route administration of medroxyprogesterone acetate (MAP) at high doses in the treatment of advanced breast cancer: clinical results.
    Guarnieri A; Tucci E; D'Aniello C; Carli A; Mariani L; De Stefano A; Nardi P
    Chemioterapia; 1984 Oct; 3(5):320-3. PubMed ID: 6241848
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Medroxyprogesterone acetate (MAP) in high doses in the treatment of breast cancer in advanced stages].
    Pannuti F; Di Marco AR; Martoni A; Fruet F; Strocchi E; Burroni P; Marraro D
    Minerva Ginecol; 1982 Nov; 34(11):977-9. PubMed ID: 7155427
    [No Abstract]   [Full Text] [Related]  

  • 5. [Urinary hydroxyproline in advanced breast carcinoma and response to treatment with medroxyprogesterone acetate (MAP) in high doses].
    Martoni A; Pedelini G; Colalongo G; Biagi R; Mambelli M; Jafelice G; Rocchetta G; Piana E; Pannuti F
    Minerva Med; 1980 Sep; 71(31):2215-9. PubMed ID: 7422143
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Modern prospects in the treatment of cancer of the breast and its metastasis. Medroxyprogesterone in massive doses as an alternative to polychemotherapy].
    Pannuti F
    Minerva Chir; 1977 Oct; 32(19):1211-20. PubMed ID: 593576
    [No Abstract]   [Full Text] [Related]  

  • 7. [Overall evaluation of the results of treatment of metastatic carcinomas of the breast with high doses of MAP combined with bromocryptin].
    Mussa A; Dogliotti L; Di Carlo F
    Minerva Med; 1980 Feb; 71(6):391-400. PubMed ID: 7360379
    [No Abstract]   [Full Text] [Related]  

  • 8. Effects of combined tamoxifen and medroxyprogesterone treatment on coagulation-fibrinolytic systems in patients with advanced breast cancer.
    Fukutomi T; Adachi I; Watanabe T; Nanasawa T; Yamamoto H
    Acta Oncol; 1993; 32(5):573-4. PubMed ID: 8217244
    [No Abstract]   [Full Text] [Related]  

  • 9. [Medroxyprogesterone acetate (MAP) and aminoglutethimide (AG) in metastatic breast carcinoma. Preliminary report on a phase II study of the German Cancer Society's Internal Medicine Oncology Task Force].
    Wander HE; Nagel GA; Blossey HC
    Onkologie; 1982 Aug; 5 Suppl():28-33. PubMed ID: 6215600
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II evaluation of oral medroxyprogesterone acetate in advanced breast cancer: a Northern California Oncology Group Study.
    Tan YO; Hendrickson C; McWhirter K; Kohler M; Hannigan JF; Carlson RW
    Cancer Treat Rep; 1987 Oct; 71(10):969-70. PubMed ID: 2958131
    [No Abstract]   [Full Text] [Related]  

  • 11. Hormone therapy in advanced breast cancer: high dose medroxyprogesterone acetate (MAP) vs tamoxifen (TMX). Preliminary results.
    Pannuti F; Martoni A; Fruet F; Strocchi E; Di Marco AR
    Eur J Cancer (1965); 1980; Suppl 1():93-8. PubMed ID: 6459237
    [No Abstract]   [Full Text] [Related]  

  • 12. [Results of the treatment of patients with advanced breast with large doses of medroxyprogesterone acetate].
    Zulichowska J; Krawczyk J; Glińska H
    Pol Tyg Lek; 1988 May; 43(22):712-4. PubMed ID: 2976163
    [No Abstract]   [Full Text] [Related]  

  • 13. [Results of a pilot study with high-dose medroxyprogesterone acetate in the treatment of metastasizing breast carcinoma].
    Castiglione M; Cavalli F
    Schweiz Med Wochenschr; 1980 Jul; 110(27-28):1073-6. PubMed ID: 7423153
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Massive-dose progestational therapy in oncology (medroxyprogesterone). Preliminary results.
    Pannuti F; Martoni A; Pollutri E; Camera P; Losinno F; Giusti H
    Panminerva Med; 1976; 18(3-4):129-36. PubMed ID: 176620
    [No Abstract]   [Full Text] [Related]  

  • 15. [Treatment of advanced cancer of the breast with synhetic progestational hormones].
    Dogliotti GC; Gavosto F; Molinatti GM
    Minerva Med; 1968 Oct; 59(81):4283-96. PubMed ID: 5686148
    [No Abstract]   [Full Text] [Related]  

  • 16. [High-dosed gestagen therapy of the metastatic mammary carcinoma (author's transl)].
    Firusian N; Becher R
    Strahlentherapie; 1981 Dec; 157(12):808-12. PubMed ID: 7330909
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New regimen of combination hormone therapy (ME-TA-MAP) in the treatment of advanced breast cancer. A pilot study.
    Pannuti F; Martoni A; Fruet ; Marraro D; Strocchi E
    Panminerva Med; 1981; 23(3):157-60. PubMed ID: 7335366
    [No Abstract]   [Full Text] [Related]  

  • 18. [Oral high-dose medroxyprogesterone acetate (MPA) in the treatment of advanced and recurrent breast cancer: a dose-response evaluation].
    Tominaga T; Izuo M; Nomura Y; Kubo K; Abe O; Enomoto K; Takatani O
    Gan To Kagaku Ryoho; 1982 Nov; 9(11):1994-2004. PubMed ID: 6223590
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical trial of combined hormone therapy (MAP + TAM) for metastatic breast cancer.
    Pannuti F; Martoni A; Piana E; Tomasi L; Grieco A; Farris A; Saccani F; Baroni M
    Chemioterapia; 1984 Aug; 3(4):211-5. PubMed ID: 6241846
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Medroxyprogesterone acetate as glucocorticoid in combination with aminoglutethimide in the treatment of metastatic breast cancer].
    Blossey HC; Wander HE; Nagel GA; Köbberling J; Kleeberg U
    Onkologie; 1982 Aug; 5 Suppl():34-41. PubMed ID: 6290955
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.